Breast Cancer Risk Assessment and Screening in Transgender Patients

被引：21

作者：

Pivo, Sarah ^{[1
]}

Montes, Jennifer ^{[2
]}

Schwartz, Shira ^{[2
]}

Chun, Jennifer ^{[2
]}

Kiely, Deirdre ^{[2
]}

Hazen, Alexes ^{[3
]}

Schnabel, Freya ^{[2
]}

机构：

[1] NYU, Sch Med, Langone Med Ctr, New York, NY USA

[2] NYU, Dept Surg, Langone Med Ctr, New York, NY 10016 USA

[3] NYU, Dept Plast Surg, Langone Med Ctr, New York, NY USA

来源：

CLINICAL BREAST CANCER | 2017年 / 17卷 / 05期

关键词：

Female-to-male (FtM); Gender confirmation surgery; High risk breast cancer; Male-to-female (MtF); Surveillance; SOCIETY GUIDELINES; FEMALE; UPDATE; MAMMOGRAPHY; MANAGEMENT; MASTECTOMY; HEALTH; WOMEN; MODEL; SEX;

D O I：

10.1016/j.clbc.2016.08.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cases of breast cancer have been reported in transgender patients; however, because this occurrence is so rare, no evidence-based screening guidelines exist for this complicated patient population, and there are no formal recommendations for surgery selection in this population. We present the case of a 36-year-old female-to-male transgender patient with a strong family history of BRCA-negative premenopausal breast cancer. Because of the patient's high-risk status, the patient underwent bilateral total mastectomy with reconstruction to produce a male-appearing chest. Breast cancer risk assessment should be performed in all transgender patients; if the patient desires top surgery, a full risk assessment is essential in selecting appropriate surgical intervention. Postsurgical surveillance should be performed, as appropriate, given risk factors and choice of surgery. Given the dearth of large population series and the small number of cases of cancer in the transgender population, a registry should be produced among providers of care to the transgender population to allow evidence-based guidelines to be formulated. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：E225 / E227

页数：3

共 23 条

[21] Using clinical factors and mammographic breast density to estimate breast cancer risk: Development and validation of a new predictive model [J].